北京大学医学部肿瘤学博士，美国加州大学旧金山分校（UCSF）医学肿瘤中心访问学者。北京大学肿瘤医院乳腺肿瘤内科主任医师，乳腺肿瘤内科党支部书记，北京大学肿瘤医院临床研究管理委员会委员，北京大学肿瘤医院基因检测工作专家委员会委员。擅长乳腺癌的内科治疗，尤其擅长早期和晚期乳腺癌的化疗，靶向治疗，内分泌治疗和免疫治疗为基础的精准个体化综合治疗，注重乳腺癌患者的全程化管理。主持中国抗癌协会、吴阶平医学基金会，以及北京医学奖励基金会的多项课题。参与全球多中心和全国多中心前瞻性新药临床研究百余项，在国内外期刊发表学术论文数十篇。作为执笔人之一，参与《首届中国进展期乳腺癌共识指南》的编著。兼任中国抗癌协会乳腺癌专业委员会委员，中国女医师协会乳腺专业委员会常委，中国医药教育协会肿瘤临床科研专业委员会常委，中国中医药研究促进会中西医多学科肿瘤防治专业委员会常委，北京慢性病防治与健康教育研究会乳腺肿瘤专业委员会常委等学术职务。主要研究方向为乳腺癌的精准诊治。
发表论文
发表76篇论文，SCI文章41篇，其中第一作者15篇。
1. Tan Y, Jiang H, Tian X, Ma F, Wang J, Zhang P, Xu B, Fan Y, Zhao W. Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter and Retrospective Study. Breast Cancer (Dove Med Press). 2025 Jan 24;17:67-78. （共同第一作者）
2. Liu J, Zhang J, Li H, Song G, Di L, Jiang H, Yan Y, Wang H, Wang J, Liu X, Shao B, Li Q. Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study. BMC Cancer. 2025 Jan 3;25(1):9.
3. Tan Y, Peng Z, Jiang H, Ma F, Wang J, Zhang P, Li Q, Tian X, Han Y, Ji D, Xu B, Zhao W, Fan Y. Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: a multicenter real-world study. Ther Adv Med Oncol. 2024 Nov 16;16:17588359241292256.
4. Liao Y, Tan Y, Li Y, Ma F, Wang J, Zhang P, Li Q, Li Q, Luo Y, Lan B, Chen S, Xu B, Jiang H, Zhao W, Fan Y. The different sequences of CDK4/6 inhibitor and mTOR inhibitor in HR+/HER2-advanced breast cancer: A multicenter real-world study. Heliyon. 2024 Sep 19;10(19):e38147.（共同通讯）
5. Zhu A, Wang N, Yun Z, Liu X, Liang X, Yan Y, Shao B, Jiang H, Di L, Song G, Li H. HER2 status results in an unstable switch from primary to recurrent breast cancer. Neoplasma. 2024 Aug;71(4):392-401.
6. Jiang H, Zhong J, Wang J, Song G, Di L, Shao B, Zhang R, Liu Y, Zhu A, Wang N, Li H. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China. Cancer Med. 2024 May;13(10):e7249.
7. Zhong J, Jiang H, Liu X, Liao H, Xie F, Shao B, Jia S, Li H. Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Apr;204(3):617-629.
8. 王环, 李惠平, 宋国红, 邸立军, 邵彬, 姜晗昉, 梁旭, 严颖, 张如艳, 冉然, 张嘉扬, 刘雅昕, 刘笑然, 王晶. 乳腺癌合并间质性肺疾病患者的临床特征及治疗情况[J]. 癌症进展, 2024, 22 (03): 257-261.
9. Tan Y, Jiang H, Ma F, Wang J, Zhang P, Li Q, Tian X, Xu B, Zhao W, Fan Y. Efficacy of everolimus-based therapy in advanced triple-positive breast cancer: Experience from three cancer centers in China. Thorac Cancer. 2023 Dec;14(34):3397-3405.（共同第一）
10. Liu Y, Song G, Di L, Jiang H, Ran R, Zhang R, Zhang Y, Li H. Three-Week Versus 4-Week Schedule of nab-Paclitaxel in Patients With Metastatic Breast Cancer: A Randomized Phase II Study. Oncologist. 2023 Dec 11;28(12):1102-e1302.
11. Zhang R, Chen Y, Liu X, Gui X, Zhu A, Jiang H, Shao B, Liang X, Yan Y, Zhang J, Song G, Li H. Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting. Front Oncol. 2023 Jun 16;13:1076469.
12. Jiang H, Li H, Song G, Di L, Shao B, Yan Y, Liu X, Chen Y, Zhang R, Ran R, Liu Y, Gui X, Wang N, Wang H. Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study. Breast Cancer Res Treat. 2023 May;199(1):67-79.
13. Shao B, Li H, Liu X, Song G, Jiang H, Yan Y, Zhang R, Ran R, Zhang J, Liu Y, Wang H, Wang J, Di L. The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study. Ann Transl Med. 2023 Jan 31;11(2):45.
14. Jiang H, Ouyang Q, Yin Y, Tong Z, Shen K, Yuan Z, Geng C, Liu Y, Song G, Ran R, Li W, Qu Q, Wang M, Meng L, Tong Y, Li H. Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis. Eur J Cancer. 2022,176:1-12.
15. Shao B, Liu X, Li H, Song G, Di L, Jiang H, Yan Y, Zhang R, Ran R, Zhang J, Liu Y, Wang H, Wang J. Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer. Curr Oncol. 2022 Aug 25;29(9):6154-6166.
16. Shao B, Li H, Zhang J, Liu X, Song G, Jiang H, Yan Y, Wang H, Wang J, Di L. The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR+HER2- metastatic breast cancer: a retrospective study. Ann Transl Med. 2022 Aug;10(16):901.
17. Liang X, Xue J, Ge X, Li J, Li H, Xue L, Di L, Tang W, Song G, Li Q, Jiang H, Zhao W, Lin F, Shao B, Yang X, Wu Z, Zhang T, Wang C, Guo Y. Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors. Front Oncol. 2022 Aug 5;12:971594.
18. Zhu A, Yun Z, You M, Liu X, Liang X, Yan Y, Shao B, Jiang H, Di L, Song G, Li H. Surgical reduction in chest wall disease to prolong survival in breast cancer patients: a retrospective study. Gland Surg. 2022 Jun;11(6):1015-1025.
19. Zhang L, Song G, Shao B, Xu L, Xiao Y, Wang M, Sumou IK, Zhang Y, Liang X, Jiang H, Li H. The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis. Anticancer Drugs. 2022 Jan 1;33(1):e635-e643.
20. Jiang H, Zhang R, Liu X, Ran R, Zhang J, Liu Y, Gui X, Chen Y, Li K, Shao B, Yan Y, Liang X, Song G, Di L, Li H. Bilateral breast cancer in China: A 10-year single-center retrospective study (2006-2016). Cancer Med. 2021，10(17):6089-6098.
21. Li H, Song G, Zhou Q, Ran R, Jiang H, Zhang R, Liu Y, Zhang J, Meng L, Ma L, Sun Y, Wang M, Zhou Q, Yan H, Zhou Q, Dong X, Tong Y. Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer. Breast Cancer Res Treat. 2021 Oct;189(3):725-736.
22. Li H, Geng C, Zhao H, Jiang H, Song G, Zhang J, Liu Y, Gui X, Wang J, Li K, Tong Z, Zhao F, Yang J, Chen G, Liu Q, Liang X. Multicenter phase II study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis. Chin J Cancer Res. 2021 Apr 30;33(2):243-255.
23. Jiang H, Li H. Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021, 21(1):149
24. Zhang R, Liu X, Huang W, Shao B, Yan Y, Liang X, Ran R, Song G, Di L, Jiang H, Li H. Clinicopathological features and prognosis of patients with pregnancy-associated breast cancer: A matched case control study. Asia Pac J Clin Oncol. 2021 Aug;17(4):396-402.
25. 陈祎霏, 严颖, 姜晗昉, 邸立军, 宋国红, 李惠平. 促性腺激素释放激素激动剂对绝经前激素受体阳性乳腺癌患者去势效果分析——真实世界研究[J]. 军事医学, 2021, 45 (05): 373-379.
26. Lei W, Li H, Song G, Zhang R, Ran R, Yan Y, Di L, Jiang H. Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China. J Cancer. 2020 Sep 23;11(22):6612-6622.
27. Wang N, Li K, Huang W, Kong W, Liu X, Shi W, Xie F, Jiang H, Song G, Di L, Wang Q, Yu J, Li H. Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing. Chin J Cancer Res. 2020 Apr;32(2):149-162.
28. Liu XR, Zhang RY, Gong H, Rugo HS, Chen LB, Fu Y, Che JW, Tie J, Shao B, Wan FL, Kong WY, Song GH, Jiang HF, Xu GB, Li HP. Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033819896331.
29. 宋国红, 李惠平, 邸立军, 严颖, 姜晗昉, 徐玲, 万冬桂, 李瑛, 王墨培, 肖宇, 张如艳, 冉然, 王环. 真实世界吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性[J]. 北京大学学报(医学版), 2020, 52 (02): 254-260.
30. 刘雅昕, 张嘉扬, 黄文发, 邵彬, 冉然, 孔维垚, 刘笑然, 李鵾, 张如艳, 严颖, 宋国红, 邸立军, 姜晗昉, 李惠平. 贝伐单抗联合化疗治疗HER2阴性晚期乳腺癌的疗效分析[J]. 肿瘤, 2019, 39 (06): 469-476.
31. 王楠, 李鹍, 李惠平, 宋国红, 邸立军, 姜晗昉, 刘笑然, 孔维垚. 铂类化疗药物对进展期三阴性乳腺癌的临床疗效及与BRCA基因突变的关系[J]. 癌症进展, 2019, 17 (04): 419-422+438.
32. Shao B, Song G, Li H, Dil L, Jiang H, Liang X, Yan Y, Zhang R, Ran R, Wang J, Liu X, You M. Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study. J BUON. 2018 Nov-Dec;23(6):1583-1590.
33. Gui X, Li H, Song G, Shao B, Jiang H. Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report. Medicine (Baltimore). 2018 Nov;97(48):e13410.
34. Liu X, Ran R, Shao B, Rugo HS, Yang Y, Hu Z, Wei Z, Wan F, Kong W, Song G, Jiang H, Liang X, Zhang R, Yan Y, Xu G, Li H. Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. Chin J Cancer Res. 2018 Jun;30(3):315-326.
35. Bao X, Sun K, Tian X, Yin Q, Jin M, Yu N, Jiang H, Zhang J, Hu Y. Present and changing trends in surgical modalities and neoadjuvant chemotherapy administration for female breast cancer in Beijing, China: A 10-year (2006-2015) retrospective hospitalization summary report-based study. Thorac Cancer. 2018 Jun;9(6):707-717.
36. 曲金荣, 王晶, 邵彬, 李惠平, 邸立军, 严颖, 宋国红, 冉然, 孔维垚, 姜晗昉, 张如艳, 刘笑然, 王环. 绝经前ER阳性HER2阴性乳腺癌转移特征分析[J]. 癌症进展, 2018, 16 (03): 366-369.
37. Liu XR, Shao B, Peng JX, Li HP, Yang YL, Kong WY, Song GH, Jiang HF, Liang X, Yan Y. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients. Breast. 2017 Apr;32:119-125.
38. Liu X, Li H, Shao B, Wu J, Kong W, Song G, Jiang H, Wang J, Wan F. Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort. Cancer Med. 2017 Mar;6(3):547-554.
39. 严颖, 邸立军, 李惠平, 宋国红, 姜晗昉, 梁旭, 邵彬, 林晓琳, 宛凤玲. 口服依托泊苷治疗难治性转移性乳腺癌的疗效及安全性[J]. 肿瘤防治研究, 2017, 44 (05): 347-350.
40. 邵彬, 李惠平, 宋国红, 邸立军, 姜晗昉, 严颖, 王环, 宛凤玲, 尤渺宁. 多西他赛对复发转移性乳腺癌免疫功能的影响[J]. 癌症进展, 2016, 14 (12): 1187-1190.
41. 严颖, 李惠平, 邸立军, 宋国红, 姜晗昉, 梁旭, 邵彬, 宛凤玲. 曲妥珠单抗治疗后进展的转移性乳腺癌继续曲妥珠单抗治疗的疗效及安全性分析[J]. 癌症进展, 2016, 14 (12): 1191-1194-1198
42. 李惠平, 冉然, 李鹍, 孔维垚, 刘笑然, 王晶, 张如艳, 邵彬, 严颖, 姜晗昉, 刘雅昕, 张嘉杨. 176例HER2阳性乳腺癌首发转移部位的分析[J]. 癌症进展, 2016, 14 (12): 1167-1169-1190.
43. 王环, 李惠平, 宋国红, 邸立军, 邵彬, 严颖, 姜晗昉, 梁旭, 宛凤玲, 张如艳, 冉然, 刘笑然, 王晶, 孔维垚. 预防性使用粒细胞集落刺激因子对乳腺癌辅助化疗所致中性粒细胞减少的影响[J]. 肿瘤, 2016, 36 (11): 1239-1245.
44. 严颖, 邸立军, 李惠平, 宋国红, 姜晗昉, 梁旭, 邵彬, 林晓琳, 宛凤玲. 拉帕替尼治疗HER2阳性转移性乳腺癌的疗效和安全性[J]. 肿瘤, 2016, 36 (11): 1246-1253.
45. 张如艳, 李惠平, 严颖, 邵彬, 宋国红, 邸立军, 姜晗昉, 冉然, 王环. 妊娠相关乳腺癌33例临床病理特征及预后分析[J]. 癌症进展, 2016, 14 (06): 535-538-541.
46. 严颖, 邸立军, 李惠平, 宋国红, 姜晗昉, 梁旭, 邵彬, 宛凤玲, 王晶. 早期乳腺癌(新)辅助曲妥珠单抗治疗心脏安全性研究[J]. 肿瘤, 2016, 36 (05): 567-573
47. 张敬南, 伍远航, 李浙民, 周军, 李永恒, 刘毅强, 唐磊, 王雪娟, 郭宏杰, 方玉, 姜晗昉, 李子禹, 张小田, 沈琳. 1例HER2阳性胃癌肝肺转移患者的MDT治疗[J]. 实用肿瘤杂志, 2016, 31 (02): 115-121
48. 邵彬, 李惠平, 邸立军, 宋国红, 姜晗昉, 梁旭, 王超颖, 严颖, 林晓琳, 王丽娜, 宛凤玲, 袁艳华, 尤渺宁. 外周血淋巴细胞亚群监测对复发转移性乳腺癌的预测及预后价值[J]. 北京大学学报(医学版), 2016, 48 (02): 304-309.
49. Jiang H，Rugo HS. Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Ther Adv Med Oncol. 2015 Nov;7(6):321-39.
50. Liang X, Yan Y, Wang L, Song G, DI L, Jiang H, Wang C, Li H. First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. Oncol Lett. 2015 Feb;9(2):987-993.
51. 邵彬, 李惠平, 朱军, 邸立军, 宋国红, 姜晗昉, 梁旭, 王超颖, 严颖, 林晓琳, 王丽娜, 宛凤玲, 袁艳华, 尤渺宁. 复发转移性乳腺癌患者血浆miRNA表达水平与临床病理特征、化疗疗效及预后关系的研究[J]. 癌症进展, 2015, 13 (02): 106-113-139.
52. 邵彬, 张洁, 吕敏, 祝毓琳, 余靖, 姜晗昉, 任军, 宋国红, 朱步东, 车利, 贾军, 梁旭, 王超颖, 严颖, 林晓琳, 黄晓蕾, 尤渺宁, 王小利, 周心娜, 邸立军. 自体外周血造血干细胞支持下高剂量化疗对晚期乳腺癌患者的生活质量研究[J]. 肿瘤防治研究, 2015, 42 (02): 145-149.
53. Liang X, Di L, Song G, Yan Y, Wang C, Jiang H, Li H. Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer. Chin J Cancer Res. 2014 Oct;26(5):550-7.
54. 梁旭, 严颖, 林晓琳, 宋国红, 姜晗昉, 王超颖, 邵彬, 宛凤灵, 李惠平, 邸立军. 亮丙瑞林微球药物性卵巢功能去势联合芳香化酶抑制剂治疗绝经前复发或转移性乳腺癌患者的临床研究[J]. 肿瘤, 2014, 34 (10): 941-945
55. 王丽娜, 严颖, 李惠平, 赵红梅, 雷玉涛, 宋国红, 姜晗昉, 梁旭, 王超颖, 邵彬. 男性乳腺癌25例的临床病理特征及生存分析[J]. 癌症进展, 2014, 12 (01): 64-69.
56. Ren J, Di L, Song G, Yu J, Jia J, Zhu Y, Yan Y, Jiang H, Liang X, Che L, Zhang J, Wan F, Wang X, Zhou X, Lyerly HK. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin Transl Oncol. 2013 Oct;15(10):780-8.
57. Liang X, Zhang J, Zhu Y, Lu Y, Zhou X, Wang Z, Yu J, Yan Y, Di L, Che L, Jiang H, Shao B, Wang X, Yang H, Lyerly HK, Ren J. Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients. Clin Transl Oncol. 2013 Apr;15(4):331-4.
58. 姜晗昉，李惠平，王超颖，严颖，宋国红，邵彬，梁旭，邸立军。白蛋白结合型紫杉醇治疗晚期乳腺癌的临床观察。肿瘤，2013,33（3）：251-257
59. 李惠平, Hope.S.Rugo, 张瑾, 张频, 刘荫华, 李波, 李席如, 杨俊兰, 孙强, 吴炅, 陈佳艺, 耿翠芝, 王涛, 修典荣, 李青, 邸立军, 宋国红, 姜晗昉, 郭卫东, 苏乌云, 袁芃, 戚晓东, 康骅, 张嘉庆. 首届中国进展期乳腺癌共识指南(草案)[J]. 癌症进展, 2013, 11 (06): 500-505.
60. 邵彬, 余靖, 邸立军, 宋国红, 朱步东, 车利, 贾军, 姜晗昉, 祝毓琳, 梁旭, 张洁, 王超颖, 严颖, 吕敏, 林晓琳, 黄晓蕾, 尤渺宁, 王小利, 周心娜, 任军. 乳腺癌恶性胸腔积液的临床特征及预后因素分析[J]. 肿瘤防治研究, 2013, 40 (04): 381-387
61. 邵彬, 余靖, 祝毓琳, 张洁, 姜晗昉, 邸立军, 宋国红, 朱步东, 车利, 贾军, 梁旭, 王超颖, 严颖, 吕敏, 林晓, 黄晓蕾, 尤渺宁, 王小利, 周心娜, 任军. 高复发风险乳腺癌患者术后紫杉醇联合塞替哌大剂量辅助化疗的临床研究[J]. 肿瘤, 2013, 33 (04): 334-338.
62. Ma B, Jiang H, Jia J, Di L, Song G, Yu J, Zhu Y, Lu Z, Wang X, Zhou X, Ren J. Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells. Clin Transl Oncol. 2012 Oct;14(10):764-73.
63. Dong N, Yu J, Wang C, Zheng X, Wang Z, Di L, Song G, Zhu B, Che L, Jia J, Jiang H, Zhou X, Wang X, Ren J. Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. J Cancer Res Clin Oncol. 2012 Jul;138(7):1197-203.
64. 姜晗昉，方健，任军，邸立军，宋国红，车利，余靖，祝毓琳。全身化疗同步或序贯脑放疗治疗非小细胞肺癌脑转移患者的疗效与毒副反应。中华肿瘤杂志，2011，33（1），58-62
65. Jing Yu, Jun Ren, Li-jun Di, Guo-hong Song, Yu-lin Zhu, Jie Zhang, Xu Liang, Li Che, Han-fang Jiang, Jun Jia, Chun-rong Zhang. Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulation factor in breast cancer patients. Chin J Cancer Res,2011，23（1），49-53
66. 余靖, 邸立军, 宋国红, 车利, 姜晗昉, 祝毓琳, 梁旭, 贾军, 张洁, 杨化兵, 王小利, 周心娜, 任军. 多西他赛联合塞替派与多西他赛联合卡培他滨治疗转移性乳腺癌的随机、对照临床研究[J]. 北京大学学报(医学版), 2011, 43 (01): 151-156
67. 姜晗昉, 宋国红, 车利, 邸立军, 任军. 口服小剂量环磷酰胺节拍疗法治疗晚期转移性乳腺癌23例临床分析[J]. 中国肿瘤临床, 2011, 38 (02): 104-107.
68. 邵彬, 余靖, 邸立军, 宋国红, 祝毓琳, 张洁, 梁旭, 车利, 姜晗昉, 贾军, 尤缈宁, 黄晓蕾, 王小利, 周心娜, 任军, 张春荣, 孟松娘, 杨玉琴, 高敏, 黄晓红, 谢嵘. 多西他赛联合重组人粒细胞集落刺激因子动员乳腺癌患者外周血干细胞的效果及影响因素分析[J]. 肿瘤防治研究, 2011, 38 (06): 666-670.
69. 祝毓琳, 邵彬, 余靖, 邸立军, 宋国红, 张洁, 梁旭, 车利, 姜晗昉, 贾军, 尤缈宁, 张春荣, 孟松娘, 杨玉琴, 高敏, 黄晓红, 谢嵘, 王小利, 周心娜, 任军. 紫杉醇联合重组人粒细胞集落刺激因子动员乳腺癌患者外周血干细胞的效果及影响因素[J]. 肿瘤防治研究, 2011, 38 (04): 404-407.
70. 姜晗昉, 邸立军, 宋国红, 余靖, 祝毓林, 王小利, 贾军, 车利, 任军. 大剂量化疗治疗高危和复发转移性乳腺癌致粒细胞缺乏症并发热的临床分析[J]. 中华肿瘤防治杂志, 2010, 17 (24): 2045-2048.
71. 车利, 任军, 邸立军, 宋国红, 余靖, 贾军, 姜晗昉, 祝毓琳, 梁旭, 王小利. GCDFP-15对乳腺癌卵巢转移的诊断价值[J]. 肿瘤防治研究, 2009, 36 (11): 944-949.
72. 姜晗昉, 任军. 小鼠骨髓间充质干细胞接种小鼠肝癌组织诱发肝癌细胞坏死[J]. 北京大学学报(医学版), 2008, (05): 453-458.
73. 马博, 任军, 姜晗昉, 贾军. 肿瘤源性外切体负载的间充质干细胞抗肿瘤活性的实验研究[J]. 北京大学学报(医学版), 2008, (05): 494-499
74. Ren J, Jia J, Zhang H, Zhang L, Ma B, Jiang H, Di L, Song G, Yu J. Dendritic cells pulsed with alpha-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma. Cancer Sci. 2008 Jul;99(7):1420-6. doi: 10.1111/j.1349-7006.2008.00820.x.
75. 姜晗昉, 任军, 崔勇, 张晓鹏. 小鼠原位移植性肝癌模型的建立及其磁共振表现[J]. 现代肿瘤医学, 2007, (02): 174-176.
76. 姜晗昉 张拥波 刘凌 曾凡荣. 老年急性脑卒中患者诊治时间的观察.重庆医学，1999，28（9）：348-349
